🇺🇸 Oxaliplatin for injection in United States
49 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 49
Most-reported reactions
- Myelosuppression — 13 reports (26.53%)
- Neuropathy Peripheral — 6 reports (12.24%)
- Lethargy — 5 reports (10.2%)
- Anaphylactic Shock — 4 reports (8.16%)
- Diarrhoea — 4 reports (8.16%)
- Dyspnoea — 4 reports (8.16%)
- Nausea — 4 reports (8.16%)
- Epistaxis — 3 reports (6.12%)
- Hypokalaemia — 3 reports (6.12%)
- Hypotension — 3 reports (6.12%)
Other Oncology approved in United States
Frequently asked questions
Is Oxaliplatin for injection approved in United States?
Oxaliplatin for injection does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Oxaliplatin for injection in United States?
Shanghai Junshi Bioscience Co., Ltd. is the originator. The local marketing authorisation holder may differ — check the official source linked above.